PDF(Pubmed)
Abstract：
UNASSIGNED: There is evidence of a modest reduction in skin cancer risk among metformin users. However, no studies have further examined the effects of metformin on melanoma survival and safety outcomes. This study aimed to quantitatively summarize any influence of metformin on the overall survival (OS) and immune-related adverse effects (irAEs) in melanoma patients.
UNASSIGNED: Selection criteria: The inclusion criteria were designed based on the PICOS principles. Information sources: PubMed, EMBASE, Cochrane Library, and Web of Science were searched for relevant literature published from the inception of these databases until November 2023 using \'Melanoma\' and \'Metformin\' as keywords. Survival outcomes were OS, progression-free survival (PFS), recurrence-free survival (RFS), and mortality; the safety outcome was irAEs. Risk of bias and data Synthesis: The Cochrane tool for assessing the risk of bias in randomized trial 2 (RoB2) and methodological index for non-randomized studies (MINORS) were selected to assess the risk of bias. The Cochrane Q and I 2 statistics based on Stata 15.1 SE were used to test the heterogeneity among all studies. Funnel plot, Egger regression, and Begg tests were used to evaluate publication bias. The leave-one-out method was selected as the sensitivity analysis tool.
UNASSIGNED: A total of 12 studies were included, involving 111,036 melanoma patients. The pooled HR for OS was 0.64 (95% CI [0.42, 1.00], p = 0.004, I2 = 73.7%), HR for PFS was 0.89 (95% CI [0.70, 1.12], p = 0.163, I2 = 41.4%), HR for RFS was 0.62 (95% CI [0.26, 1.48], p = 0.085, I2 = 66.3%), and HR for mortality was 0.53 (95% CI [0.46, 0.63], p = 0.775, I2 = 0.0%). There was no significant difference in irAEs incidence (OR = 1.01; 95% CI [0.42, 2.41]; p = 0.642) between metformin and no metformin groups.
UNASSIGNED: The improvement in overall survival of melanoma patients with metformin may indirectly result from its diverse biological targets and beneficial effects on multiple systemic diseases. While we could not demonstrate a specific improvement in the survival of melanoma patients, the combined benefits and safety of metformin for patients taking the drug are worthy of recognition.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024518182.
UNASSIGNED: Selection criteria: The inclusion criteria were designed based on the PICOS principles. Information sources: PubMed, EMBASE, Cochrane Library, and Web of Science were searched for relevant literature published from the inception of these databases until November 2023 using \'Melanoma\' and \'Metformin\' as keywords. Survival outcomes were OS, progression-free survival (PFS), recurrence-free survival (RFS), and mortality; the safety outcome was irAEs. Risk of bias and data Synthesis: The Cochrane tool for assessing the risk of bias in randomized trial 2 (RoB2) and methodological index for non-randomized studies (MINORS) were selected to assess the risk of bias. The Cochrane Q and I 2 statistics based on Stata 15.1 SE were used to test the heterogeneity among all studies. Funnel plot, Egger regression, and Begg tests were used to evaluate publication bias. The leave-one-out method was selected as the sensitivity analysis tool.
UNASSIGNED: A total of 12 studies were included, involving 111,036 melanoma patients. The pooled HR for OS was 0.64 (95% CI [0.42, 1.00], p = 0.004, I2 = 73.7%), HR for PFS was 0.89 (95% CI [0.70, 1.12], p = 0.163, I2 = 41.4%), HR for RFS was 0.62 (95% CI [0.26, 1.48], p = 0.085, I2 = 66.3%), and HR for mortality was 0.53 (95% CI [0.46, 0.63], p = 0.775, I2 = 0.0%). There was no significant difference in irAEs incidence (OR = 1.01; 95% CI [0.42, 2.41]; p = 0.642) between metformin and no metformin groups.
UNASSIGNED: The improvement in overall survival of melanoma patients with metformin may indirectly result from its diverse biological targets and beneficial effects on multiple systemic diseases. While we could not demonstrate a specific improvement in the survival of melanoma patients, the combined benefits and safety of metformin for patients taking the drug are worthy of recognition.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024518182.
摘要：
■有证据表明二甲双胍使用者患皮肤癌的风险有一定程度的降低。然而,没有研究进一步研究二甲双胍对黑色素瘤生存和安全性结局的影响.本研究旨在定量总结二甲双胍对黑色素瘤患者总生存期（OS）和免疫相关不良反应（irAEs）的影响。
■选择标准：纳入标准是根据PICOS原则设计的。信息来源:PubMed,EMBASE,科克伦图书馆,从这些数据库开始到2023年11月，使用“黑色素瘤”和“二甲双胍”作为关键词，搜索了WebofScience发布的相关文献。生存结果是OS，无进展生存期（PFS），无复发生存率（RFS），和死亡率；安全性结果是错误的。偏倚风险和数据综合：选择用于评估随机试验2中偏倚风险的Cochrane工具（RoB2）和非随机研究方法学指数（MINORS）来评估偏倚风险。使用基于Stata15.1SE的CochraneQ和I2统计数据来检验所有研究之间的异质性。漏斗图，Egger回归，和Begg检验用于评估发表偏倚。选择留一法作为灵敏度分析工具。
■共纳入12项研究，涉及111036例黑色素瘤患者。OS的合并HR为0.64(95%CI[0.42，1.00]，p=0.004,I2=73.7%),PFS的HR为0.89（95%CI[0.70，1.12]，p=0.163，I2=41.4%），RFS的HR为0.62（95%CI[0.26，1.48]，p=0.085,I2=66.3%),死亡率为0.53（95%CI[0.46，0.63]，p=0.775，I2=0.0%）。二甲双胍组和无二甲双胍组之间的irAE发生率无显著差异(OR=1.01;95%CI[0.42,2.41];p=0.642)。
■使用二甲双胍的黑色素瘤患者的总生存期的改善可能是由于其不同的生物学靶标和对多种全身性疾病的有益作用间接导致的。虽然我们无法证明黑色素瘤患者的生存率有特定的改善，二甲双胍对服用该药物患者的综合益处和安全性值得肯定。
■https://www.crd.约克。AC.英国/PROSPERO/,标识符CRD42024518182。
■选择标准：纳入标准是根据PICOS原则设计的。信息来源:PubMed,EMBASE,科克伦图书馆,从这些数据库开始到2023年11月，使用“黑色素瘤”和“二甲双胍”作为关键词，搜索了WebofScience发布的相关文献。生存结果是OS，无进展生存期（PFS），无复发生存率（RFS），和死亡率；安全性结果是错误的。偏倚风险和数据综合：选择用于评估随机试验2中偏倚风险的Cochrane工具（RoB2）和非随机研究方法学指数（MINORS）来评估偏倚风险。使用基于Stata15.1SE的CochraneQ和I2统计数据来检验所有研究之间的异质性。漏斗图，Egger回归，和Begg检验用于评估发表偏倚。选择留一法作为灵敏度分析工具。
■共纳入12项研究，涉及111036例黑色素瘤患者。OS的合并HR为0.64(95%CI[0.42，1.00]，p=0.004,I2=73.7%),PFS的HR为0.89（95%CI[0.70，1.12]，p=0.163，I2=41.4%），RFS的HR为0.62（95%CI[0.26，1.48]，p=0.085,I2=66.3%),死亡率为0.53（95%CI[0.46，0.63]，p=0.775，I2=0.0%）。二甲双胍组和无二甲双胍组之间的irAE发生率无显著差异(OR=1.01;95%CI[0.42,2.41];p=0.642)。
■使用二甲双胍的黑色素瘤患者的总生存期的改善可能是由于其不同的生物学靶标和对多种全身性疾病的有益作用间接导致的。虽然我们无法证明黑色素瘤患者的生存率有特定的改善，二甲双胍对服用该药物患者的综合益处和安全性值得肯定。
■https://www.crd.约克。AC.英国/PROSPERO/,标识符CRD42024518182。
